{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T17:31:42Z","timestamp":1769275902015,"version":"3.49.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T00:00:00Z","timestamp":1694822400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T00:00:00Z","timestamp":1694822400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s40120-023-00539-9","type":"journal-article","created":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T06:02:08Z","timestamp":1694844128000},"page":"2041-2052","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Natalizumab Treatment of Relapsing Remitting Multiple Sclerosis Has No Long-Term Effects on the Proportion of Circulating Regulatory T Cells"],"prefix":"10.1007","volume":"12","author":[{"given":"Radu","family":"Tanasescu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nanci","family":"Frakich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.-Jun","family":"Chou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Perla","family":"Filippini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulio","family":"Podda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gao","family":"Xin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ranjithmenon","family":"Muraleedharan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oltita","family":"Jerca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Onion","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2066-7585","authenticated-orcid":false,"given":"Cris S.","family":"Constantinescu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,9,16]]},"reference":[{"issue":"1","key":"539_CR1","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1111\/j.1600-065X.2012.01127.x","volume":"248","author":"Y Takeshita","year":"2012","unstructured":"Takeshita Y, Ransohoff RM. Inflammatory cell trafficking across the blood-brain barrier: chemokine regulation and in vitro models. Immunol Rev. 2012;248(1):228\u201339. https:\/\/doi.org\/10.1111\/j.1600-065X.2012.01127.x.","journal-title":"Immunol Rev"},{"issue":"9","key":"539_CR2","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa044397","volume":"354","author":"CH Polman","year":"2006","unstructured":"Polman CH, O\u2019Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899\u2013910. https:\/\/doi.org\/10.1056\/NEJMoa044397.","journal-title":"N Engl J Med"},{"issue":"1","key":"539_CR3","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1212\/WNL.0000000000000541","volume":"83","author":"P O'Connor","year":"2014","unstructured":"O\u2019Connor P, Goodman A, Kappos L, Lublin F, Polman C, Rudick RA, et al. Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study. Neurology. 2014;83(1):78\u201386. https:\/\/doi.org\/10.1212\/WNL.0000000000000541.","journal-title":"Neurology"},{"issue":"11","key":"539_CR4","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/S1474-4422(17)30282-X","volume":"16","author":"PR Ho","year":"2017","unstructured":"Ho PR, Koendgen H, Campbell N, Haddock B, Richman S, Chang I. Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies. Lancet Neurol. 2017;16(11):925\u201333. https:\/\/doi.org\/10.1016\/S1474-4422(17)30282-X.","journal-title":"Lancet Neurol"},{"key":"539_CR5","doi-asserted-by":"publisher","first-page":"175628641983780","DOI":"10.1177\/1756286419837809","volume":"12","author":"L Prosperini","year":"2019","unstructured":"Prosperini L, Kinkel RP, Miravalle AA, Iaffaldano P, Fantaccini S. Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis. Ther Adv Neurol Disord. 2019;12:1756286419837809. https:\/\/doi.org\/10.1177\/1756286419837809.","journal-title":"Ther Adv Neurol Disord"},{"issue":"2","key":"539_CR6","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000210","volume":"3","author":"K Kimura","year":"2016","unstructured":"Kimura K, Nakamura M, Sato W, Okamoto T, Araki M, Lin Y, et al. Disrupted balance of T cells under natalizumab treatment in multiple sclerosis. Neurol (R) Neuroimmunol Neuroinflamm. 2016;3(2): e210. https:\/\/doi.org\/10.1212\/NXI.0000000000000210.","journal-title":"Neurol (R) Neuroimmunol Neuroinflamm"},{"issue":"22","key":"539_CR7","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1212\/WNL.0b013e3181a8266f","volume":"72","author":"P Kivisakk","year":"2009","unstructured":"Kivisakk P, Healy BC, Viglietta V, Quintana FJ, Hootstein MA, Weiner HL, et al. Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells. Neurology. 2009;72(22):1922\u201330. https:\/\/doi.org\/10.1212\/WNL.0b013e3181a8266f.","journal-title":"Neurology"},{"key":"539_CR8","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jneuroim.2017.05.006","volume":"309","author":"A Carotenuto","year":"2017","unstructured":"Carotenuto A, Scalia G, Ausiello F, Moccia M, Russo CV, Sacca F, et al. CD4\/CD8 ratio during natalizumab treatment in multiple sclerosis patients. J Neuroimmunol. 2017;309:47\u201350. https:\/\/doi.org\/10.1016\/j.jneuroim.2017.05.006.","journal-title":"J Neuroimmunol"},{"issue":"1","key":"539_CR9","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1177\/1756285615615257","volume":"9","author":"F Sellebjerg","year":"2016","unstructured":"Sellebjerg F, Cadavid D, Steiner D, Villar LM, Reynolds R, Mikol D. Exploring potential mechanisms of action of natalizumab in secondary progressive multiple sclerosis. Ther Adv Neurol Disord. 2016;9(1):31\u201343. https:\/\/doi.org\/10.1177\/1756285615615257.","journal-title":"Ther Adv Neurol Disord"},{"key":"539_CR10","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/897249","volume":"2014","author":"M Meira","year":"2014","unstructured":"Meira M, Sievers C, Hoffmann F, Rasenack M, Kuhle J, Derfuss T, et al. Unraveling natalizumab effects on deregulated miR-17 expression in CD4+ T cells of patients with relapsing-remitting multiple sclerosis. J Immunol Res. 2014;2014: 897249. https:\/\/doi.org\/10.1155\/2014\/897249.","journal-title":"J Immunol Res"},{"issue":"6","key":"539_CR11","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000292","volume":"3","author":"M Saraste","year":"2016","unstructured":"Saraste M, Penttila TL, Airas L. Natalizumab treatment leads to an increase in circulating CXCR3-expressing B cells. Neurol Neuroimmunol Neuroinflamm. 2016;3(6): e292. https:\/\/doi.org\/10.1212\/NXI.0000000000000292.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"11","key":"539_CR12","doi-asserted-by":"publisher","first-page":"802","DOI":"10.3390\/brainsci10110802","volume":"10","author":"S Maier","year":"2020","unstructured":"Maier S, Simu M, Hutanu A, Barcutean L, Voidazan S, Bajko Z, et al. Clinical immunological correlations in patients with multiple sclerosis treated with natalizumab. Brain Sci. 2020;10(11):802. https:\/\/doi.org\/10.3390\/brainsci10110802.","journal-title":"Brain Sci"},{"issue":"12","key":"539_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0052208","volume":"7","author":"TF Benkert","year":"2012","unstructured":"Benkert TF, Dietz L, Hartmann EM, Leich E, Rosenwald A, Serfling E, et al. Natalizumab exerts direct signaling capacity and supports a pro-inflammatory phenotype in some patients with multiple sclerosis. PLoS ONE. 2012;7(12): e52208. https:\/\/doi.org\/10.1371\/journal.pone.0052208.","journal-title":"PLoS ONE"},{"issue":"11","key":"539_CR14","doi-asserted-by":"publisher","first-page":"3411","DOI":"10.1093\/brain\/awz301","volume":"142","author":"S Herich","year":"2019","unstructured":"Herich S, Schneider-Hohendorf T, Rohlmann A, KhaleghiGhadiri M, Schulte-Mecklenbeck A, Zondler L, et al. Human CCR5high effector memory cells perform CNS parenchymal immune surveillance via GZMK-mediated transendothelial diapedesis. Brain: J Neurol. 2019;142(11):3411\u201327. https:\/\/doi.org\/10.1093\/brain\/awz301.","journal-title":"Brain: J Neurol"},{"issue":"3","key":"539_CR15","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1093\/brain\/awz017","volume":"142","author":"I Mexhitaj","year":"2019","unstructured":"Mexhitaj I, Nyirenda MH, Li R, O\u2019Mahony J, Rezk A, Rozenberg A, et al. Abnormal effector and regulatory T cell subsets in paediatric-onset multiple sclerosis. Brain: J Neurol. 2019;142(3):617\u201332. https:\/\/doi.org\/10.1093\/brain\/awz017.","journal-title":"Brain: J Neurol"},{"key":"539_CR16","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.3389\/fimmu.2017.01981","volume":"8","author":"L Vangelista","year":"2017","unstructured":"Vangelista L, Vento S. The expanding therapeutic perspective of CCR5 blockade. Front Immunol. 2017;8:1981. https:\/\/doi.org\/10.3389\/fimmu.2017.01981.","journal-title":"Front Immunol"},{"issue":"6","key":"539_CR17","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1172\/JCI5150","volume":"103","author":"TL Sorensen","year":"1999","unstructured":"Sorensen TL, Tani M, Jensen J, Pierce V, Lucchinetti C, Folcik VA, et al. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J Clin Invest. 1999;103(6):807\u201315. https:\/\/doi.org\/10.1172\/JCI5150.","journal-title":"J Clin Invest"},{"issue":"10","key":"539_CR18","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1038\/ejhg.2011.88","volume":"19","author":"HB Sondergaard","year":"2011","unstructured":"Sondergaard HB, Sellebjerg F, Hillert J, Olsson T, Kockum I, Linden M, et al. Alterations in KLRB1 gene expression and a Scandinavian multiple sclerosis association study of the KLRB1 SNP rs4763655. Eur J Hum Genet. 2011;19(10):1100\u20133. https:\/\/doi.org\/10.1038\/ejhg.2011.88.","journal-title":"Eur J Hum Genet"},{"issue":"Pt 2","key":"539_CR19","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1093\/brain\/awq354","volume":"134","author":"V Annibali","year":"2011","unstructured":"Annibali V, Ristori G, Angelini DF, Serafini B, Mechelli R, Cannoni S, et al. CD161(high)CD8+T cells bear pathogenetic potential in multiple sclerosis. Brain. 2011;134(Pt 2):542\u201354. https:\/\/doi.org\/10.1093\/brain\/awq354.","journal-title":"Brain"},{"key":"539_CR20","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.jaut.2017.10.005","volume":"88","author":"B Nicol","year":"2018","unstructured":"Nicol B, Salou M, Vogel I, Garcia A, Dugast E, Morille J, et al. An intermediate level of CD161 expression defines a novel activated, inflammatory, and pathogenic subset of CD8(+) T cells involved in multiple sclerosis. J Autoimmun. 2018;88:61\u201374. https:\/\/doi.org\/10.1016\/j.jaut.2017.10.005.","journal-title":"J Autoimmun"},{"issue":"3","key":"539_CR21","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.medj.2021.01.006","volume":"2","author":"M Kaufmann","year":"2021","unstructured":"Kaufmann M, Evans H, Schaupp AL, Engler JB, Kaur G, Willing A, et al. Identifying CNS-colonizing T cells as potential therapeutic targets to prevent progression of multiple sclerosis. Med (N Y). 2021;2(3):296-312.e8. https:\/\/doi.org\/10.1016\/j.medj.2021.01.006.","journal-title":"Med (N Y)"},{"issue":"287","key":"539_CR22","doi-asserted-by":"publisher","first-page":"287ra74","DOI":"10.1126\/scitranslmed.aaa8038","volume":"7","author":"Y Cao","year":"2015","unstructured":"Cao Y, Goods BA, Raddassi K, Nepom GT, Kwok WW, Love JC, et al. Functional inflammatory profiles distinguish myelin-reactive T cells from patients with multiple sclerosis. Sci Transl Med. 2015;7(287):287ra74. https:\/\/doi.org\/10.1126\/scitranslmed.aaa8038.","journal-title":"Sci Transl Med"},{"issue":"5","key":"539_CR23","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.4049\/jimmunol.0713169","volume":"182","author":"A Liston","year":"2009","unstructured":"Liston A, Kohler RE, Townley S, Haylock-Jacobs S, Comerford I, Caon AC, et al. Inhibition of CCR6 function reduces the severity of experimental autoimmune encephalomyelitis via effects on the priming phase of the immune response. J Immunol. 2009;182(5):3121\u201330. https:\/\/doi.org\/10.4049\/jimmunol.0713169.","journal-title":"J Immunol"},{"issue":"5","key":"539_CR24","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1038\/ni.1716","volume":"10","author":"A Reboldi","year":"2009","unstructured":"Reboldi A, Coisne C, Baumjohann D, Benvenuto F, Bottinelli D, Lira S, et al. C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. Nat Immunol. 2009;10(5):514\u201323. https:\/\/doi.org\/10.1038\/ni.1716.","journal-title":"Nat Immunol"},{"issue":"2","key":"539_CR25","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162\u201373. https:\/\/doi.org\/10.1016\/S1474-4422(17)30470-2.","journal-title":"Lancet Neurol"},{"issue":"3","key":"539_CR26","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","volume":"83","author":"FD Lublin","year":"2014","unstructured":"Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sorensen PS, Thompson AJ, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83(3):278\u201386. https:\/\/doi.org\/10.1212\/WNL.0000000000000560.","journal-title":"Neurology"},{"issue":"11","key":"539_CR27","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1212\/wnl.33.11.1444","volume":"33","author":"JF Kurtzke","year":"1983","unstructured":"Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33(11):1444\u201352. https:\/\/doi.org\/10.1212\/wnl.33.11.1444.","journal-title":"Neurology"},{"key":"539_CR28","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3389\/fimmu.2011.00036","volume":"2","author":"JR Fergusson","year":"2011","unstructured":"Fergusson JR, Fleming VM, Klenerman P. CD161-expressing human T cells. Front Immunol. 2011;2:36. https:\/\/doi.org\/10.3389\/fimmu.2011.00036.","journal-title":"Front Immunol"},{"issue":"10","key":"539_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0003319","volume":"3","author":"MP Stenner","year":"2008","unstructured":"Stenner MP, Waschbisch A, Buck D, Doerck S, Einsele H, Toyka KV, et al. Effects of natalizumab treatment on Foxp3+ T regulatory cells. PLoS ONE. 2008;3(10): e3319. https:\/\/doi.org\/10.1371\/journal.pone.0003319.","journal-title":"PLoS ONE"},{"issue":"7","key":"539_CR30","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1056\/NEJM199802123380706","volume":"338","author":"AD Luster","year":"1998","unstructured":"Luster AD. Chemokines\u2013chemotactic cytokines that mediate inflammation. N Engl J Med. 1998;338(7):436\u201345. https:\/\/doi.org\/10.1056\/NEJM199802123380706.","journal-title":"N Engl J Med"},{"issue":"9","key":"539_CR31","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1001\/jamaneurol.2020.1118","volume":"77","author":"R Tanasescu","year":"2020","unstructured":"Tanasescu R, Tench CR, Constantinescu CS, Telford G, Singh S, Frakich N, et al. Hookworm treatment for relapsing multiple sclerosis: a randomized double-blinded placebo-controlled trial. JAMA Neurol. 2020;77(9):1089\u201398. https:\/\/doi.org\/10.1001\/jamaneurol.2020.1118.","journal-title":"JAMA Neurol"},{"issue":"6665","key":"539_CR32","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1038\/34814","volume":"391","author":"P Loetscher","year":"1998","unstructured":"Loetscher P, Uguccioni M, Bordoli L, Baggiolini M, Moser B, Chizzolini C, et al. CCR5 is characteristic of Th1 lymphocytes. Nature. 1998;391(6665):344\u20135. https:\/\/doi.org\/10.1038\/34814.","journal-title":"Nature"},{"issue":"10","key":"539_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102647","volume":"19","author":"T Moser","year":"2020","unstructured":"Moser T, Akgun K, Proschmann U, Sellner J, Ziemssen T. The role of TH17 cells in multiple sclerosis: therapeutic implications. Autoimmun Rev. 2020;19(10): 102647. https:\/\/doi.org\/10.1016\/j.autrev.2020.102647.","journal-title":"Autoimmun Rev"},{"issue":"3","key":"539_CR34","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1002\/ana.21748","volume":"66","author":"H Kebir","year":"2009","unstructured":"Kebir H, Ifergan I, Alvarez JI, Bernard M, Poirier J, Arbour N, et al. Preferential recruitment of interferon-gamma-expressing TH17 cells in multiple sclerosis. Ann Neurol. 2009;66(3):390\u2013402. https:\/\/doi.org\/10.1002\/ana.21748.","journal-title":"Ann Neurol"},{"issue":"1","key":"539_CR35","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.cyto.2009.12.003","volume":"50","author":"LJ Edwards","year":"2010","unstructured":"Edwards LJ, Robins RA, Constantinescu CS. Th17\/Th1 phenotype in demyelinating disease. Cytokine. 2010;50(1):19\u201323. https:\/\/doi.org\/10.1016\/j.cyto.2009.12.003.","journal-title":"Cytokine"},{"key":"539_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2019.106138","volume":"80","author":"S Karampoor","year":"2020","unstructured":"Karampoor S, Zahednasab H, Amini R, Esghaei M, Sholeh M, Keyvani H. Maraviroc attenuates the pathogenesis of experimental autoimmune encephalitis. Int Immunopharmacol. 2020;80: 106138. https:\/\/doi.org\/10.1016\/j.intimp.2019.106138.","journal-title":"Int Immunopharmacol"},{"issue":"3","key":"539_CR37","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s00401-015-1391-6","volume":"129","author":"L Stork","year":"2015","unstructured":"Stork L, Bruck W, Bar-Or A, Metz I. High CCR5 expression in natalizumab-associated progressive multifocal leukoencephalopathy immune reconstitution inflammatory syndrome supports treatment with the CCR5 inhibitor maraviroc. Acta Neuropathol. 2015;129(3):467\u20138. https:\/\/doi.org\/10.1007\/s00401-015-1391-6.","journal-title":"Acta Neuropathol"},{"issue":"5","key":"539_CR38","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1056\/NEJMc1304828","volume":"370","author":"PS Giacomini","year":"2014","unstructured":"Giacomini PS, Rozenberg A, Metz I, Araujo D, Arbour N, Bar-Or A, et al. Maraviroc and JC virus-associated immune reconstitution inflammatory syndrome. N Engl J Med. 2014;370(5):486\u20138. https:\/\/doi.org\/10.1056\/NEJMc1304828.","journal-title":"N Engl J Med"},{"issue":"2","key":"539_CR39","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000325","volume":"4","author":"SC Hodecker","year":"2017","unstructured":"Hodecker SC, Sturner KH, Becker V, Elias-Hamp B, Holst B, Friese MA, et al. Maraviroc as possible treatment for PML-IRIS in natalizumab-treated patients with MS. Neurol (R) Neuroimmunol Neuroinflamm. 2017;4(2): e325. https:\/\/doi.org\/10.1212\/NXI.0000000000000325.","journal-title":"Neurol (R) Neuroimmunol Neuroinflamm"},{"key":"539_CR40","doi-asserted-by":"publisher","first-page":"8437","DOI":"10.1038\/ncomms9437","volume":"6","author":"BJ Raveney","year":"2015","unstructured":"Raveney BJ, Oki S, Hohjoh H, Nakamura M, Sato W, Murata M, et al. Eomesodermin-expressing T-helper cells are essential for chronic neuroinflammation. Nat Commun. 2015;6:8437. https:\/\/doi.org\/10.1038\/ncomms9437.","journal-title":"Nat Commun"},{"key":"539_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2018.11.023","volume":"130","author":"S Oki","year":"2019","unstructured":"Oki S. Eomes-expressing T-helper cells as potential target of therapy in chronic neuroinflammation. Neurochem Int. 2019;130: 104348. https:\/\/doi.org\/10.1016\/j.neuint.2018.11.023.","journal-title":"Neurochem Int"},{"issue":"2","key":"539_CR42","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1002\/ana.25508","volume":"86","author":"J van Langelaar","year":"2019","unstructured":"van Langelaar J, Rijvers L, Janssen M, Wierenga-Wolf AF, Melief MJ, Siepman TA, et al. Induction of brain-infiltrating T-bet-expressing B cells in multiple sclerosis. Ann Neurol. 2019;86(2):264\u201378. https:\/\/doi.org\/10.1002\/ana.25508.","journal-title":"Ann Neurol"},{"issue":"1","key":"539_CR43","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2209944120","volume":"120","author":"C Janoschka","year":"2023","unstructured":"Janoschka C, Lindner M, Koppers N, Starost L, Liebmann M, Eschborn M, et al. Enhanced pathogenicity of Th17 cells due to natalizumab treatment: Implications for MS disease rebound. Proc Natl Acad Sci U S A. 2023;120(1): e22. https:\/\/doi.org\/10.1073\/pnas.2209944120. (PMID: 36574650; PMCID: PMC9910615).","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-023-00539-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-023-00539-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-023-00539-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T05:32:42Z","timestamp":1699335162000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-023-00539-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,16]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["539"],"URL":"https:\/\/doi.org\/10.1007\/s40120-023-00539-9","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,16]]},"assertion":[{"value":"4 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Radu Tanasescu received support for attending scientific meetings from AbbVie, Biogen Idec, Teva and Genzyme, and consultancy fees from Johnson & Johnson. Cris S Constantinescu received research grant support, support for attending scientific meetings, and consultancy fees from Biogen Idec, Bayer Schering, Genzyme, Merck Serono, Morphosys, Novartis, Roche, Sanofi Pasteur and Merck Sharp and Dohme & EMD Serono. Dr Constantinescu is on the editorial board of Neurology and Therapy. Nanci Frakich, I-Jun Chou, Giulio Podda, Xin Gao, Ranjithmenon Muralledharan, Olita P Jerca and David Onion have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was approved by the East Midlands Research Committee, England (11\/EM\/0341). All patients gave written informed consent. The study was conducted in accordance with the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}